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New Findings (100 words) 24 
What is the central question of this study?  25 
Endothelial dilation is impaired following an acute moderate hypoxia stimulus; therefore, the 26 
central question of this study is to investigate whether this impairment in endothelial dilation is 27 
evident following a mild hypoxic exposure, and if smooth muscle dilation is impaired following 28 
acute hypoxic exposure.     29 
What is the main findings and its importance? 30 
Vascular smooth muscle cells sensitivity to a NO is impaired following mild and moderate 31 
hypoxia equivalent to ~2000m and ~5000m respectively.  Unlike following moderate hypoxia 32 
exposure, it appears endothelial dysfunction is not impaired following mild hypoxia. These 33 
findings have important implications for individuals with pre-exiting medical conditions, 34 
especially those who are rapidly exposed to hypoxia.  35 
 36 
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Abstract (250) 47 
 48 
Vascular function is impaired at high altitude and following one hour of comparably severe 49 
normobaric hypoxia (~FIO2=0.11). Whether vascular function is impaired during milder hypoxia 50 
is unknown. We examined the hypothesis that vascular function would be impaired following 51 
acute exposure to mild (74±2 mmHg PETO₂) and moderate (50±3 mmHg PETO₂) normobaric 52 
hypoxia. Brachial endothelium-dependent flow mediated dilation (FMD) was assessed at 53 
baseline and following 30-minutes of hypoxia (n=12) or normoxia (time control trial; n=10). 54 
Endothelium-independent dilation (via glyceryl trinitrate; GTN) was assessed following the 55 
hypoxic FMD test, and in normoxia on a separate control day (n=8). Compared to normoxic 56 
baseline, allometrically correcting for baseline diameter and FMD shear rate under the curve, 57 
FMD and GTN-induced dilation were reduced following mild hypoxia (FMD: 6.4±1.0 vs. 58 
5.9±1.0%; GTN: 16.4±4.0 vs. 14.3±4.0%; P≤0.02) and moderate hypoxia (FMD: 6.6±1.0 vs. 59 
4.5±1.0%; GTN: 16.4±4.0 vs. 12.9±4.0%; ≤0.02). The normoxic time-control data, however, 60 
revealed a ~8% decline in FMD (comparable with the FMD decline during mild hypoxia), 61 
indicating that 30 minutes of recovery for repeated FMD assessments is insufficient. Considering 62 
the methodological effects of repetitive FMD testing, endothelial dilation is unaltered following 63 
mild hypoxia exposure, yet it is significantly impaired during more moderate hypoxia. Graded 64 
impairments in smooth muscle function is evident following mild and moderate hypoxia, and this 65 
has implications for individuals acutely exposed to hypoxia. 66 
 67 
 68 
  69 
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Introduction 70 
The nitric oxide (NO)-vasodilator system is important in the maintenance of vasoregulation and 71 
vascular health and its function is a marker of cardiovascular risk. Endothelium-dependent flow 72 
mediated dilation (FMD) assesses conduit artery vasodilatory capacity following a reactive 73 
hyperemia stimulus (shear stress). The latter component of the NO-dilator cascade endothelium-74 
independent NO-mediated smooth muscle relaxation can be assessed by administering glyceryl 75 
trinitrate (GTN)(Corretti et al., 2002). Therefore, the assessment of both FMD and GTN 76 
measures within subjects provides complimentary information regarding the locus of change in 77 
vascular function in vivo (Celermajer et al., 1992).     78 
 79 
The effect of acute normobaric or hypobaric hypoxia on basal FMD and GTN-induced dilation is 80 
unclear. Some studies have reported a significant decline following hypoxia (Bailey et al., 2013; 81 
Lewis et al., 2014), others an absence of change (Frick et al., 2006; Frobert et al., 2008; Bailey 82 
et al., 2013). These discrepancies are perhaps not surprising, since studies are often confounded 83 
by 1) pathology such as metabolic syndrome (Frick et al., 2006), chronic mountain sickness 84 
(Bailey et al., 2013) and cardiovascular disease (Frobert et al., 2008); or 2) methodological 85 
limitations e.g., different definition of acute hypoxic exposure (5 minutes vs. 1 hour vs. 3 days), 86 
different acute hypoxic stimuli (hypobaric hypoxia vs. normobaric hypoxia) (Frobert et al., 2008; 87 
Lewis et al., 2014), different population groups (native highlanders vs. lowlanders; (Bailey et al., 88 
2013), and/or inappropriate FMD and GTN data collection and analysis protocols [cuff 89 
placement, period of data collection, non-use of edge detection software; (Frobert et al., 2008)]. 90 
 91 
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By employing international guidelines for the assessment of FMD and endothelium-independent 92 
NO-mediated smooth muscle relaxation (Thijssen et al., 2011), we recently documented a 14% 93 
decline in both FMD and GTN-induced dilation following three days of hypobaric  hypoxia 94 
(5050m) in healthy individuals (Lewis et al., 2014). These findings suggest that endothelial and 95 
vascular smooth muscle dysfunction both contribute to a decline in the NO-vasodilator system 96 
with hypobaric hypoxia. In a follow-up study, we discovered that a substantial larger and 97 
sustained decline in FMD (~28%) occurs as a result of 60-minutes of exposure to normobaric 98 
hypoxia (FIO2=0.11; a hypoxic level stimulating ~5000m). These marked reductions in FMD 99 
were abolished following sympathetic nerve activity (SNA) blockade (Lewis et al., 2014). 100 
However, it is currently unclear whether GTN-induced dilation is impaired to the same degree 101 
within 60-minutes following normobaric hypoxia. Furthermore, it is unknown whether the 102 
impairment in FMD and potential decline in GTN-induced dilation following acute (<60-103 
minutes) normobaric hypoxia is sensitive to distinct levels of hypoxia.  104 
 105 
The primary purpose of this study was to examine the effect of acute (<60 minutes) exposure to 106 
mild (end-tidal oxygen PETO2 = 75 mm Hg; ~2000m) and moderate (end-tidal PETO2 = 50 mm 107 
Hg; ~4600m) isocapnic hypoxia on brachial FMD and GTN-induced dilation. We hypothesized 108 
that FMD and GTN-induced dilation would be impaired following mild hypoxia and more so 109 
following moderate hypoxia. We intentionally chose this mild exposure as a comparable PO2 to 110 
that encountered during commercial air travel (Smith et al., 2012), during trekking, and ski 111 
vacation sites in North America. To ensure that there were no repetitive influences of the FMD 112 
testing, we conducted a normoxic time-control study to quantify the effect of 30 minutes of 113 
supine normoxic rest on FMD. Based on previously published guidelines (Corretti et al., 2002; 114 
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Barton et al., 2011), we reasoned that FMD and related hemodynamic variables would be 115 
unaltered following 30 minutes of normoxic supine rest.   116 
 117 
Materials and Methods 118 
Participants: Twelve healthy normotensive volunteers (7 men, 5 women; mean ± SD: age, 26 ± 119 
6 years; body mass, 71 ± 12 kg; height, 176 ± 8 cm; body mass index, 23± 3 kg/m2) participated 120 
in this randomized counter-balanced experiment. The study was approved by the Human Ethics 121 
Committee of the University of British Columbia and conformed to the standards set by the 122 
Declaration of Helsinki. All volunteers provided written informed consent. Participants were 123 
non-smokers, had no previous history of cardiovascular, cerebrovascular, or respiratory diseases, 124 
and were not taking any medications, other than the contraceptive pill. Females were tested 125 
during the either the pill withdrawal/placebo phase, or in the earlier follicular phase of the 126 
menstrual cycle of consecutive cycles. All experimental testing took place at the University of 127 
British Columbia (altitude 344 m). 128 
 129 
Study design: Participants attended the laboratory on four occasions (one familiarisation session 130 
and three experimental session). The experimental sessions were separated by >7 day and each 131 
session commenced between 8:00-9:00 A.M. Experimental testing followed a minimum of 12 h 132 
abstinence from alcohol, caffeine, and strenuous exercise, and an overnight fast. Experimental 133 
session one and two consisted of 20 minutes of supine rest following which, cardiorespiratory 134 
measures were monitored for 5 minutes and the assessment of FMD was undertaken under 135 
normoxic conditions. Participants were then rapidly exposed to isocapnic hypoxia. Following 30 136 
minutes of isocapnic hypoxia exposure cardiorespiratory measures and the assessment of FMD 137 
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were repeated and following 60 minutes of isocapnic hypoxia GTN-induced dilation assessed. 138 
The level of isocapnic hypoxia experience in each session was randomized and counter-139 
balanced. Using end-tidal forcing, in the separate visits, the participant’s end-tidal oxygen 140 
(PETO2) was rapidly reduced down to 75 mm Hg (mild-hypoxia) or 50 mm Hg (moderate-141 
hypoxia) following baseline assessments. End-tidal carbon dioxide (PETCO2) was clamped as 142 
baseline levels.  143 
 144 
During experimental session three, following 20 minutes of supine rest the assessment of GTN-145 
induced dilation was made in normoxic conditions, in eight of the twelve participants who 146 
completed experimental sessions one and two. The GTN-dilation assessment was made on a 147 
separate day from the two hypoxic tests due to the half-life of GTN being approximately four 148 
hours and the potential interference with other measures if conducted at normoxia in 149 
experimental sessions one or two.     150 
 151 
Experimental Measures and Data Analysis 152 
Brachial artery vascular function: A 10 MHz multifrequency linear array probe attached to a 153 
high-resolution ultrasound machine (Terason 3000, Teratech) was used to image the brachial 154 
artery in the right arm. Blood flow velocity was measured as peak blood flow velocity of the 155 
Doppler shift, with the sample gate begin placed in the centre of the lumen. 156 
Endothelium-dependent FMD. FMD was assessed according to international guidelines 157 
(Thijssen et al., 2011). With the occluding cuff placed distal to the ultrasound probe, 1 minute of 158 
brachial diameter and blood flow velocity recordings preceded forearm cuff inflation to 220 159 
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mmHg for 5 minutes. Brachial diameter and blood flow velocity recordings resumed 30 s prior to 160 
cuff deflation and continued for 3 minutes thereafter.  161 
Endothelium-independent FMD (GTN). Following 20 minutes of rest, brachial diameter and 162 
blood flow velocity recordings were made for 1 minute prior to participants receiving a 163 
sublingual dose of glyceryl trinitrate (GTN; 400 µg spray). Brachial diameter and blood flow 164 
velocity recordings were taken continuously for a 10-minute period thereafter.  165 
 166 
Custom-designed edge-detection and wall-tracking software, which is largely independent of 167 
investigator bias, was utilised for the analysis of FMD and GTN (Woodman et al., 2001; Black 168 
et al., 2008; Thijssen et al., 2011). This software provides continuous and simultaneous 169 
diameter, blood flow velocity at 30Hz. From this synchronized diameter and velocity data, blood 170 
flow (the product of lumen cross-sectional area and Doppler velocity and shear rate (SR [4 times 171 
velocity divided by diameter]) (Pyke et al., 2004; Pyke & Tschakovsky, 2007) are calculated at 172 
30 Hz. This semi-automated software provides higher reproducibility of diameter measurements 173 
and reduces both observer error and bias with a reported intra-observer CV for FMD% of 6.7% 174 
(Woodman et al., 2001). Baseline diameter, blood flow, and SR patterns were calculated as the 175 
mean of data acquired across the minute preceding the cuff inflation period. Peak diameter after 176 
cuff deflation was automatically detected according to an algorithm that identified the maximum 177 
bracket of data, and FMD% was calculated as the percentage rise of this peak diameter from the 178 
preceding baseline diameter. The time to peak diameter (in seconds) was calculated from the 179 
point of cuff deflation to the maximum post-deflation diameter and SR area under curve (SRAUC) 180 
was calculated for the FMD stimulus up to peak diameter (Black et al., 2008). Recent evidence 181 
has highlighted that FMD% can under some circumstances fail to consider the difference in 182 
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baseline artery diameter following an intervention or between groups (Atkinson & Batterham, 183 
2013; Atkinson et al., 2013). Therefore, as outlined in detail (Atkinson & Batterham, 2013; 184 
Atkinson et al., 2013), we adopted an allometric scaling approach to adjust for baseline diameter 185 
in the calculation of FMD and GTN-induced dilation. Also, where necessary we also adjusted the 186 
FMD and GTN dilation for changes in SRAUC. These results are presented as ‘allometrically 187 
corrected’ FMD%. Oscillatory shear index, an indicator of the magnitude of shear oscillation, 188 
was defined as: (|retrograde SR|) / (|antegrade SR| + |retrograde SR|). We also calculated 189 
FMD/GTN ratio, to correct the FMD for potential differences in GTN-induced dilation.  190 
 191 
Cardiorespiratory Measures: Beat-to-beat blood pressure (BP) was measured by finger 192 
photoplethysmography (Finometer PRO, Finapress Medical Systems, Amsterdam, Netherlands) 193 
and normalized to manual cuff measurements of the brachial artery. Stroke volume (SV) and 194 
cardiac output (CO) were calculated from the BP waveform obtained from the finger 195 
photoplethysmography using the Modelflow method, incorporating age, sex, height, and weight 196 
(BeatScope 1.0 software; TNO TPD; Biomedical Instruments). Heart rate was measured (HR) 197 
via three-lead electrocardiogram (ML132; ADInstruments, Colorado Springs CO). All measures 198 
were monitored for 5 minutes prior to FMD assessment, where minute 4 to 5 was used as a 199 
representation of baseline values. Peripheral oxygen saturation (SpO2; Pulse Oximeter 200 
MD300K1; Vacumed, Ventura, CA) was measured immediately prior to the FMD assessment.  201 
 202 
For measurement of PETCO2 and PETO2, subjects breathed through a mouthpiece connected to a 203 
two-way non-rebreathing valve. Respired gas pressures were sampled at the mouth by securing a 204 
sample line connected to a calibrated online gas analyzer (model ML206, AD Instruments, 205 
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Colorado Springs, CO) into the mouthpiece. Respiratory flow was measured at the mouth using a 206 
pneumotachograph (model HR 800L, HansRudolph, Shawnee, KS). PETCO2, PETO2 and 207 
inspiratory and expiratory tidal volume were determined for each breath online using specifically 208 
designed software (LabView, Austin, TX). PETCO2 and PETO2 were controlled via end-tidal 209 
forcing system (Tymko et al., 2015). This system uses independent gas solenoid valves for 210 
oxygen, carbon dioxide and nitrogen and controls the volume of each gas delivered to the 211 
inspiratory reservoir through a mixing-and-humidification chamber. With use of feedback 212 
information regarding PETCO2, PETO2, and inspiratory and expiratory tidal volume, the system 213 
prospectively targets the inspirate to bring end-tidal gas to the desired level. Gas control was 214 
fine-tuned using a feedback control and error reduction algorithm. Clamped PETCO2 levels were 215 
determined as the values measured during the last 5-minutes of normoxic measurements.  216 
 217 
Normoxic Time-Control Study 218 
Participants: Ten healthy normotensive volunteers, (9 men, 1 women; mean ± SD: age, 27 ± 2 219 
years; body mass, 77 ± 8 kg; height, 180 ± 1 cm; body mass index, 23± 2 kg/m2) participated in 220 
this study. All participant pre-experimental considerations were the same as described for the 221 
hypoxia studies.   222 
 223 
Experimental Design and Methods: All participants were familiarised with the FMD protocol, 224 
and attended the laboratory for one experimental session. Here, FMD was assessed in normoxic 225 
conditions prior to (FMD one) and following 30 minutes of supine rest (FMD two). All 226 
methodological and data analysis procedures were performed as outlined for the hypoxia studies.      227 
 228 
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Statistical Analysis: All data were analysed using SPSS (version 21, IBM, Surrey, UK) and 229 
expressed as mean±SD. Statistical significance was defined as P≤0.05 and distribution normality 230 
confirmed using repeated Shapiro–Wilk W tests.  231 
Study 1: To examine the interaction between the experimental intervention (normoxia vs. hypoxic 232 
stimuli) and the experimental condition (PETO2 75 mmHg (mild-hypoxia) trial vs. PETO2 50 233 
mmHg (moderate-hypoxia)) a two-way repeated measures ANOVA was used; to further 234 
exposure any significant interaction effect, two-tailed paired t tests were used to quantify the 235 
effect of the hypoxic stimuli on the measures of interest. For the assessment of GTN-induced 236 
dilation and related variables, a one-way repeated measures ANOVA was used to compare the 237 
trial difference between normoxia and the two hypoxic stimuli. Pearson’s correlation analysis 238 
was used to examine the relationship between selected measures.  Normoxic time-control study To 239 
examine the interaction between normoxic baseline and following 30 minutes of supine rest a 240 
two-tailed paired t tests were used, unless stated otherwise. Hypoxia and Normoxic time-control 241 
studies: A linear mixed model for repeated measures was used to allometrically correct FMD and 242 
GTN-dilation for baseline diameter and SRAUC as covariates.  243 
 244 
Results 245 
Effect of hypoxia on cardiorespiratory variables 246 
Per the study design, a significant interaction between the experimental intervention (normoxia 247 
vs. hypoxia) and experimental condition (PETO2 75 mmHg trial vs. PETO2 50 mmHg trial) was 248 
evident for PETO2 (P<0.01). No difference in baseline (normoxia) PETO2 was evident between 249 
experimental conditions; however, as desired, PETO2 was lower following hypoxia exposure in 250 
the PETO2 50 mmHg (50 ± 3 mm Hg) versus the PETO2 75 mmHg trial (74 ± 2 mm Hg; P<0.01; 251 
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Table 1). There were no differences in PETCO2 during the experimental intervention or condition 252 
(Table 1).   	253 
 254 
A significant interaction between the experimental intervention and experimental condition was 255 
evident for ventilation (P<0.01; Table 1). Compared to normoxia, ventilation was increased 256 
following exposure to PETO2 75 mmHg (+3.1 ± 3.5 %; P=0.01) and PETO2 50 mmHg (+10.0 ± 257 
5.8 %; P<0.01); the increase in ventilation was greater following exposure to PETO2 50 mmHg 258 
(P<0.01). Likewise, a significant interaction between the experimental intervention and 259 
experimental condition was evident for SaO2 (P=0.001; Table 1). Compared to normoxia, the 260 
reductions in SaO2 were greater at PETO2 50 mm Hg compared with 75 mmHg (-15 ± 3 % vs -5 ± 261 
2 %; P<0.01).  262 
 263 
A main effect for the experimental intervention was evident for mean arterial blood pressure 264 
(MAP) independent of hypoxic stimulus; compared to normoxia, MAP increased in both hypoxic 265 
trials by 6 ± 2 mmHg (P=0.001, Table 1), respectively. An interaction between experimental 266 
intervention and experimental condition was evident for HR (P=0.01) and CO (P=0.03; Table 1). 267 
The increase in HR was greater (6 ± 4 beats·min-1; P<0.01; Table 1) in the PETO 50 mmHg trial 268 
compared with the 75 mmHg trial. Likewise, the increase in CO was greater in the PETO2 50 269 
mmHg trial (0.6 ± 0.7 L·min-1; P=0.03; Table 1). No difference was evident in the SV response 270 
following exposure to hypoxia (n= 10).  271 
 272 
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Effect of hypoxia on brachial artery baseline measures  273 
A significant interaction between the experimental intervention (normoxia vs. hypoxia) and 274 
experimental condition (PETO2 75 mmHg trial vs. PETO2 50 mmHg trial) was evident for baseline 275 
brachial arterial diameter (P=0.01). Following exposure to PETO2 50 mmHg, arterial diameter 276 
increased by 0.02 ± 0.02 cm (relative 4%; P=0.01). In contrast, no diameter changes were 277 
evident following exposure to PETO2 of 75 mmHg (P=0.80; Table 2).  278 
 279 
Compared to normoxia, independent of the level of hypoxic stimulus, significant main effects 280 
were evident for reductions in baseline peak blood velocity (-3.6 ± 2.9 cm·s-1; [relative ~-42%] 281 
P<0.01), baseline peak blood flow (-13.2 ± 9.3 ml·min-1 [relative, ~-39%; P=0.01], baseline 282 
mean SR (-37 ± 12 s [relative, ~-43%; P<0.01], baseline antegrade SR (-24 ± 7 s [relative, ~ -283 
21%; P=0.01], and an increase in baseline retrograde SR (+ -13 ± 5 s [relative, ~ +48%; P=0.01) 284 
and oscillatory shear index (+ 0.1 ± 0.0 [relative, ~+54%; P=0.01; Table 2 and Figure 1). A 285 
significant interaction between intervention (normoxia vs. hypoxia) and experimental condition 286 
(PETO2 75 mmHg trial vs. PETO2 50 mmHg trial) was evident for baseline retrograde SR and 287 
oscillatory shear index (P≤0.01); the intervention change following exposure to PETO2 50 mmHg 288 
was greater (retrograde SR: +-18 ± 9 s; oscillatory shear index +0.12 ± 0.0) than exposure to 289 
PETO2 75 mm Hg (retrograde SR: +-8 ± 2 s; oscillatory shear index: 0.07 ± 0.0; P≤0.03; Figure 290 
1).  291 
 292 
Effect of hypoxia on brachial artery FMD (n=12) 293 
A significant interaction between the experimental intervention and experimental condition was 294 
evident for FMD (P<0.01; Figure 2 A). Compared to normoxia, FMD was significantly reduced 295 
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following exposure to PETO2 75 mmHg (-1.1 ±1.1% [relative, ~ -17%]); P=0.005) and PETO2 50 296 
mmHg (-3.1 ±1.7 % [relative 45%]; P<0.01); the decline in FMD was greater following exposure 297 
to PETO2 50 mmHg by 2 ±1 % [relative 63%; P<0.01]. A significant main effect for intervention 298 
was evident for SRAUC (P=0.01). Here, compared to normoxia, SRAUC (25855 ± 9699 AUC) was 299 
reduced following hypoxia exposure (19441 ± 10386 AUC) independent of hypoxic stimulus 300 
(Table 2). Following allometric scaling of FMD and accounting for the decline in SRAUC as a 301 
covariate, a significant interaction between experimental intervention and experimental condition 302 
was evident (P<0.01). Compared to normoxia, FMD was significantly reduced following 303 
exposure to PETO2 75 mmHg (-0.5% [relative -8%]), but the decline following the 30 minutes 304 
exposure to PETO2 50 mmHg was greater (-2.1% [relative, ~-32%]; Figure 2B). 305 
 306 
Effect of hypoxia on brachial artery GTN (n=8; Table 3) 307 
One-way ANOVA revealed that GTN-induced dilation was reduced following hypoxic exposure 308 
(P=0.01); Figure 3A). Compared with normoxia, GTN-induced dilation was significantly 309 
decreased following exposure to PETO2 75 mmHg (-2.1 ± 2.5 % [relative -12%] and PETO2 50 310 
mmHg (-4.2 ± 4.0 % [relative -25%]). The decline with PETO2 50 mmHg was greater than the 311 
decline observed with PETO2 75 mmHg by 2.1 ± 2.6 %; [relative 14%; P=0.06; Figure 3). 312 
Following allometric scaling for baseline diameter, GTN-dilation was still significantly 313 
decreased following exposure to PETO2 75 mmHg (-2.1% [relative -13%] and even more so 314 
following PETO2 50 mmHg (-3.5% [relative -22%]; P=0.02; Figure 3B). Compared to normoxia, 315 
the FMD:GTN ratio was significantly decreased following exposure to PETO2 75 mmHg (-0.05 ± 316 
0.03 % [relative 11%] and PETO2 50 mmHg (-0.16 ± 0.04 % [relative 35%] P<0.01). The decline 317 
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in the FMD:GTN ratio was significantly greater following exposure to PETO2 50 mmHg than 318 
PETO2 75 mmHg (P=0.02; Table 3).  319 
 320 
Normoxic time-control study 321 
Baseline MAP, HR, and SaO2 % were 80 ± 6 mmHg, 56 ± 8 beats·min-1, 98 ± 1 %. No 322 
significant difference in baseline diameter was evident following 30 minutes of supine rest 323 
(Table 4). Compared to baseline (pre-FMD one), however, reductions in baseline peak blood 324 
flow velocity (-5.8 ± 1.2 cm·s-1; [relative ~36%] P=0.01), peak blood flow (-0.98 ± 0.32 ml·min-1 325 
[relative, ~37%; <0.01]), were evident following 30 minutes of supine rest (Table 4). Reduction 326 
in baseline mean SR (~-37 ± 8 s [relative, ~-34%]; P<0.04) and baseline anterograde SR (-32 ± 8 327 
s [relative, ~ -27%]; P=0.06) were evident following FMD one and 30 minutes of supine rest, 328 
retrograde SR and oscillatory SR index were not significantly changed (P=0.19; Table 4). 329 
Compared to FMD one, FMD was significantly reduced following 30 minutes of supine rest by -330 
0.62 ± 0.28 % (relative, ~ -8.4%; P=0.02). No significant difference in FMD SRAUC was evident 331 
between the two FMDs (P=0.13; Table 4).  Following allometric scaling of FMD, where baseline 332 
diameter and SRAUC were considered as a covariate, the decline in FMD following 30 minutes of 333 
supine rest still evident (P=0.05, Figure 4).   334 
 335 
Discussion 336 
The primary aim of study one was to examine the acute effects (<60 minutes) of a mild (PETO2 337 
75 mm Hg; ~2000m) and moderate (PETO2 50 mm Hg; ~5000m) isocapnic normobaric hypoxic 338 
stimulus on the NO-vasodilator system via the assessment of FMD and GTN-induced dilation in 339 
the brachial artery. The novel findings were: 1) Compared to normoxia, FMD and GTN-induced 340 
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dilation were reduced following moderate hypoxia and, to a lesser extent, following mild 341 
hypoxia. 2) FMD SRAUC was reduced during both moderate and mild hypoxic conditions; 342 
however, when the decline in FMD was corrected for the decline in SRAUC, the decline in FMD 343 
with mild and moderate hypoxia were attenuated. 3) Following exposure to both mild and 344 
moderate hypoxia there was a decline in baseline blood flow and anterograde SR, and an 345 
increase in retrograde SR. The increase in retrograde SR was greater during moderate hypoxia. 346 
The main findings of the normoxic time-control study were that baseline blood flow and blood 347 
flow velocity along with FMD were all reduced following 30 minutes of supine normoxic rest. 348 
Such findings indicate that 30 minutes of recovery time for repeated FMD assessments is 349 
insufficient. Based on these findings, the following discussion outlines putative mechanisms that 350 
likely underpin hypoxia-induced declines in vascular function, including:  1) methodological 351 
considerations of repetitive FMD testing and data interpretation; 2) hypoxic-induced declines in 352 
FMD SRAUC; 3)  an increase in oscillatory shear; and 4) impaired endothelial function and 353 
smooth muscle vasodilation.  354 
 355 
Methodological considerations of repetitive FMD testing: The initial finding of this study 356 
revealed an acute decline in FMD following 30-minutes of isocapnic hypoxia, which appears to 357 
be dependent on the severity of the hypoxic stimulus. FMD was reduced by (relative) ~17% and 358 
~45% following 30 minutes of mild (PETO2 75 mm Hg, Sa02 93%) and moderate (PETO2 50 mm 359 
Hg, Sa02 83%) hypoxia, respectively. The SRAUC component of the FMD provides an estimation 360 
of the shear stress stimulus created upon cuff release, which ultimately provokes the production 361 
and release of NO from the endothelium. In both hypoxic trials, FMD SRAUC decreased by 362 
~25%, a finding which was not evident in our normoxic time-control trial. Although not 363 
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statistically significant, SRAUC has previously been reported to be reduced by ~21% following 364 
60-minutes of hypoxia, and appears to recover to pre-hypoxic levels following ~6-hours of 365 
hypoxic exposure (Lewis et al., 2014). When we accounted for the decline in FMD SRAUC in our 366 
covariate analyses, we found the relative decline in FMD with mild hypoxia (-17% to -8%) and 367 
moderate hypoxia (-45% to -32%) was attenuated by ~9%. These results suggest the decline in 368 
FMD with hypoxia is partly due to a decline in FMD SRAUC.  Although the mechanisms 369 
influencing the decline in FMD SRAUC with acute hypoxia are unknown, we speculate the 370 
possibility that forearm sympathetic constraint following hypoxic (Weisbrod et al., 2001) 371 
exposure may have hindered the ischemic response to FMD cuff occlusion, and resulted in a 372 
lower reactive hyperemic response on cuff release. Nevertheless, as discussed next, other 373 
mechanism(s) also appear to affect the decline in FMD with moderate hypoxia.    374 
 375 
A strength of our study was that we conducted a normoxic time-control trial to rule out any 376 
influence of repetitive FMD testing. Had we not have done this control, we would have falsely 377 
concluded a major influence of mild hypoxia on FMD. Our data indicates that a repeated 378 
assessment of FMD following 30 minutes of supine rest is reduced by 8%. Although not 379 
mentioned in the recent FMD guidelines (Thijssen et al., 2011), the original International 380 
Brachial Artery Reactivity Task Force (Corretti et al., 2002) states that at least 10 minutes of 381 
supine rest is needed after reactive hyperemia before another assessment is conducted. More 382 
recently, it was reported that repeated measures of FMD in the brachial artery may be taken after 383 
a minimum of 5 minutes or as soon as the vessel has returned to its baseline diameter (Barton et 384 
al., 2011). In light of these studies, 30 minutes of supine rest between FMD assessment in the 385 
current studies should have been conservative recovery period, especially since baseline arterial 386 
18	
	
	
	
diameter was unchanged in the time-control study or following mild hypoxia exposure. Arterial 387 
diameter was larger following moderate hypoxia exposure; however, this was likely due to the 388 
effect of moderate hypoxia and has been accounted for in our interpretations of the data 389 
(allometric scaling). In summary, at least in our experimental study with a highly experienced 390 
(>1000 FMD tests and established high reducibility) vascular scanner it appears 30 minutes of 391 
recovery for repeated FMD assessments is insufficient, and should be considered in future 392 
research. 393 
 394 
Given that the relative decline in FMD following  mild hypoxia exposure (-8%) was comparable 395 
to that seen in the time-control study it is likely that the decline in FMD following acute mild 396 
exposure was due to lasting effect of the baseline (normoxic) FMD assessment. Nevertheless, 397 
even if we consider the 8% decline in FMD due to the negative impact of repeated measures, a 398 
relative decline of 24% in FMD is still present following moderate hypoxia. We have previously 399 
(Lewis et al., 2014) documented a ~28% decline in FMD following 60-minutes of normobaric 400 
hypoxia (FIO2=0.11; SaO2 79%), supporting the current findings of an acute impairment in FMD 401 
following moderate hypoxia.  402 
 403 
Alterations in baseline blood flow and oscillatory shear patterns: Pre-FMD baseline blood 404 
flow velocity and blood flow were reduced by ~42% and ~39%, respectively, following hypoxic 405 
exposure. Declines in brachial artery blood flow (-11%) and blood flow velocity (-2%) have 406 
previously been reported following 10 minutes of moderate hypoxia (FIO2 0.12) (Iwamoto et al., 407 
2015). Given that the decline in blood flow velocity / blood flow was comparably reduced 408 
following hypoxic exposure (39-42%) and in our normoxic time control trial (~36-37%)), it is 409 
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possible long lasting effects of forearm ischemia from the baseline FMD may have altered blood 410 
velocity hemodynamics and explain this decline in blood flow prior to repeated assessment of 411 
FMD. The topics require further investigation as it clearly have important methodological 412 
considerations in the design of related vascular function experiments.  413 
 414 
Significant change in baseline SR patterns were evident with hypoxia, with a decrease in 415 
antegrade SR (~21%) and an increase in retrograde SR (~48%), and oscillatory shear index 416 
(~54%). No significant changes in SR patterns were evident in the normoxic time-control study, 417 
therefore, it appears the alteration in SR were an effect of hypoxia. This is supported by others 418 
who have reported an increase in retrograde SR (>39%) and oscillatory shear index (>35%) 419 
following 10 minutes of hypoxia (FIO2 0.12) (Iwamoto et al., 2015; Katayama et al., 2016). 420 
Although hypoxia causes net vasodilation (Heistad & Wheeler, 1970), sympathetic excitation 421 
within 5-10 minutes of isocapnic hypoxia (SaO2 85%) exposure has been shown to mask the 422 
vasodilation effects of hypoxia in the resistant vessels of the forearm (Weisbrod et al., 2001; 423 
Weisbrod et al., 2004). Additionally, acute excitation and elimination of sympathetic nerve 424 
activity on forearm vascular resistant has been shown to increase and reduce retrograde and 425 
oscillatory SR patterns respectively, in the brachial artery (Thijssen et al., 2009; Padilla et al., 426 
2010; Casey et al., 2012; Padilla et al., 2014). Therefore, it is possible that heightened 427 
sympathetic vasoconstrictor activity with acute hypoxia (Dinenno et al., 2003) and subsequently 428 
hypoxic vasodilation constraint in the forearm (Weisbrod et al., 2001) could have increased 429 
downstream resistance vessel tone, and altered SR blood flow patters.  430 
 431 
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The increase in retrograde and oscillatory SR patterns in the current study was significantly 432 
larger following exposure to moderate vs. mild hypoxic exposure. Acute and progressive 433 
increases in baseline retrograde and oscillatory SR patterns in the brachial artery have been 434 
shown to elicit a dose-dependent impairment in brachial FMD (Thijssen et al., 2009). 435 
Furthermore, graded reductions in hypoxia have been shown to elicit a graded increase in MSNA 436 
(Rowell et al., 1989), and graded increase in MSNA have been was associated with an 437 
incremental increase in retrograde and oscillatory SR patterns (Padilla et al., 2010). Therefore, it 438 
is possible that a greater increase in SNA with moderate hypoxic exposure possibly explains the 439 
larger increase in retrograde and oscillatory SR patterns in this condition and the significant 440 
impairment in FMD, this concept warrant future investigation. 441 
 442 
Impaired vascular smooth muscle and endothelial vasodilation: The GTN-induced dilation in 443 
the current study was reduced by (relative) ~13% and ~22% following 60-minutes of mild and 444 
moderate hypoxia, respectively. We have previously reported a decline (relative: ~14%) in GTN-445 
induced dilation following 3-days at 5050m (Lewis et al., 2014); however, as far as we are 446 
aware, this is the first report of acute effects of hypoxia on GTN-induced vasodilation. Given 447 
that the assessment GTN-induced dilation represents vascular smooth muscle cell sensitivity to 448 
NO (Corretti et al., 2002; Maruhashi et al., 2013), the findings of the current study supports the 449 
notion of impairment in vascular smooth muscle function following hypoxic exposure (Lewis et 450 
al., 2014). This reduction in GTN-induced dilation undoubtedly influence the impairment 451 
observed in FMD responses, especially following moderate hypoxia. However, currently what 452 
level of impairment in smooth muscle function is required to hinder upon FMD measures is 453 
currently unknown.  454 
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The acute decline in FMD following 60-minutes of normobaric hypoxia has previously been 455 
shown to be partially reversed following an a1-adrenoreceptor blockade, suggesting 456 
sympathoexcitation is one of the mechanisms by which FMD is impaired following acute 457 
hypoxic exposure (Weisbrod et al., 2004; Lewis et al., 2014). Although the effect of hypoxic-458 
induced sympathoexcitation on the acute impairment in GTN-induced dilation has not been 459 
reported, it is likely a key mechanism for reductions in FMD (Saito et al., 1988; Rowell et al., 460 
1989) i.e., via increasing vascular smooth muscle tone and impairing vascular smooth muscle 461 
cell ability to relax in response to NO.   462 
 463 
Previous work has reported a ~20% increase in muscle sympathetic nerve activity (MSNA) 464 
following 5-minutes of isocapnic hypoxia (FIO2=0.10; SaO2 82%) (Somers et al., 1988). 465 
Moreover, Rowell et al., (1989) reported an inverse relationship between graded reductions in 466 
FIO2 and elevations in MSNA. For example, after 20-minutes of hypoxia at FIO2 0.12 and FIO2 467 
0.10, MSNA was elevated by ~90% and 250%, respectively (Rowell et al., 1989). The duration 468 
that MSNA remains elevated during an acute hypoxic insult, and its potential effect on GTN-469 
induced dilation and FMD are currently unknown and warrant investigation. Furthermore, since 470 
the magnitude of hypoxic-induced elevations in MSNA seems to be dependent on the severity of 471 
the hypoxic stimulus, this could also explain why the degree of FMD and GTN-induced dilation 472 
impairment were larger following the moderate hypoxic exposure compared to the mild hypoxic 473 
exposure in the current study. Future studies combining MSNA measures with and without SNA 474 
blockade are needed to clearly test this hypothesis.  475 
 476 
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When we corrected our assessments of FMD with the changes in GTN induced dilation with 477 
hypoxia, we found that FMD-to-GTN% was decreased by ~ 35% from normoxia moderate 478 
hypoxic exposure. The FMD-to-GTN ratio represents global NO-dependent vasodilator function 479 
(Spence et al., 2013; Lewis et al., 2014); thus, following 30-minutes of moderate hypoxia it 480 
appears the decline in FMD is partly due to endothelial dysfunction in addition to vascular 481 
smooth muscle dysfunction.  482 
 483 
Implications 484 
It has been estimated that a 1% absolute reduction in FMD is associated with a 9% increase in 485 
cardiovascular disease risk (Green et al., 2012); thus, 2% absolute decline in FMD with 486 
moderate isocapnic Keephypoxia in the current study is potentially associated with an elevation 487 
in cardiovascular disease risk. This may potentially have some health implications for 488 
individuals acutely exposed to moderate hypoxia, such as Heli hikes / skiing activities. Acute 489 
impairment in smooth muscle dilation may potentially have implications for individuals exposed 490 
to mild and moderate hypoxia during air travel. Medical issues during air travel are estimated at 491 
about 350 per day worldwide, and currently aircraft carrying passengers are pressurized and 492 
maintain a cabin altitude between 1525m to 2438 m (Sohail & Fischer, 2005). One study 493 
investigated the change in SpO2 levels in healthy flight-crew members during 22 scheduled 494 
flights, and found mean SpO2 nadir levels fell from 97% (preflight) to 88.6% at cruising altitude 495 
(Cottrell et al., 1995). Therefore, air travel has the potential to exacerbate risk for passengers 496 
with underlying cardiovascular conditions, and increase the risk of medical events. Furthermore, 497 
although factors in addition to the mild hypoxemia likely also play a role (e.g. diet, shift work, 498 
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sleep patterns) flight attendants have a 3.5 fold increase risk of developing cardiovascular disease 499 
compared to the general public (McNeely et al., 2014).  500 
 501 
Conclusion  502 
In light of the methodological effects of repetitive FMD testing, there does not appear to be an 503 
impairment in endothelial function following mild hypoxia exposure. However, there is 504 
significant endothelial impairment following moderate hypoxic exposure and our data indicate 505 
that this impairment is potentially influenced by adverse changes in SR patters and increase in 506 
oscillatory SR with graded increases in hypoxia. Graded impairments in smooth muscle cell 507 
sensitivity to NO is evident following mild and moderate hypoxia, and has important 508 
implications for individuals acutely exposed to mild and moderate hypoxia, especially those with 509 
cardiovascular risk factors.   510 
 511 
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Figure Captions 666 
 667 
Figure 1: Effect of normoxia (baseline) and acute isocapnic hypoxia (PETO2 75 mmHg and 668 
PETO2 50 mmHg) on pre-FMD baseline shear rate (SR) patterns and oscillatory shear index. * 669 
Significant main effect for intervention (normoxia vs hypoxia), P=0.01. † Significant interaction 670 
between intervention and condition, P=0.04, the increase from normoxic baseline in retrograde 671 
SR and oscillatory shear index with hypoxia was greater in the PETO2 50 mmHg trial compared 672 
to PETO2 75 mmHg. 673 
 674 
Figure 2: The effect of normoxia and acute isocapnic hypoxia (PETO2 75 mmHg and PETO2 50 675 
mmHg) on FMD. A) Uncorrected and B) corrected for significant changes in baseline arterial 676 
diameter and shear rate area under the curve. * Significant main effect for intervention 677 
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(normoxia vs hypoxia), P<0.01. † Significant main effect for condition (PETO2 75 mmHg vs 678 
PETO2 50 mmHg), P<0.01. ‡ Significant interaction between intervention and condition, P<0.01.  679 
 680 
Figure 3: The effect of normoxia and acute isocapnic hypoxia (PETO2 75 mmHg and PETO2 50 681 
mmHg) on GTN dilation; A) uncorrected and B) corrected for significant changes in pre-GTN 682 
arterial diameter. * Significant main effect for intervention (normoxia vs hypoxia), P=0.05. † 683 
Significant main effect for condition (PETO2 75 mmHg vs PETO2 50 mmHg), P<0.01. ‡ 684 
Significant interaction between intervention and condition, P=0.01. 685 
 686 
Figure 4: Mean and SD uncorrected and corrected (for baseline arterial diameter and shear rate 687 
area under the curve). * (paired t-test) † (linear mix model) Post 30-min significantly different 688 
from baseline; P≤0.05.   689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
 704 
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Tables  705 
 706 
Table 1: Effect of normoxia and acute isocapnic hypoxia (PETO2 75 mmHg and PETO2 50 707 
mmHg) on cardiorespiratory variables. 708 
 709 
Experimental Condition  PETO2 75 mmHg  PETO2  50 mmHg    
Experimental Intervention  Normoxia Hypoxia Normoxia Hypoxia  
Ventilation (L·min) 12.4 ± 2.7 15.1 ± 3.8 12.8 ± 2.1 22.3 ± 6.7 * † ‡ 
PETO2 (mmHg) 92.0 ± 4.7 74.0± 1.6 92.6 ± 5.8 50.0 ± 2.8 * † ‡ 
PETCO2 (mmHg) 40.8 ± 2.2 40.9± 2.0 41.3 ± 2.4 41.0 ± 2.4  
MAP (mmHg) 85 ± 14 93 ± 16 85 ± 13 90 ± 15 † 
SBP (mmHg) 106 ± 22 108 ± 27 107 ± 27 117 ± 25 † 
DBP (mmHg) 64 ± 8 69 ± 8 64 ± 9 65 ± 11 † 
HR (beats·min-1) 58 ± 13 57 ± 12 64 ± 13 64 ± 11 * † ‡ 
SV (ml) 103 ± 27 106 ± 30 107 ± 21 106 ± 23  
CO (L·min) 5.5 ± 1.1 6.0 ± 1.3 5.6 ± 1.1 6.7 ± 1.4 † ‡ 
SaO2 (%) 97 ± 1 93 ± 2 97 ± 1 83 ± 3 * † ‡ 
 710 
Values expressed as mean ± SD: End-tidal oxygen (PETO2), end-tidal carbon dioxide (PETCO2), 711 
mean arterial blood pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure 712 
(DBP), heart rate (HR), stroke volume (SV, n=10), cardiac output (CO, n=10), oxygen saturation 713 
(SaO2). * Significant main effect for intervention (normoxia vs hypoxia), P≤0.04. † Significant 714 
main effect for condition (PETO2 75 mmHg vs. PETO2 50 mmHg), P≤0.04. ‡ Significant 715 
interaction between intervention and condition, P≤0.02. 716 
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Table 2: Effect of normoxia (baseline) and acute isocapnic hypoxia on FMD related variables.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values expressed as mean ± SD: Shear rate area under the curve (SRAUC); Flow mediated dilation (FMD). * Significant main effect for 
intervention (normoxia vs hypoxia), P<0.01. † Significant main effect for hypoxic condition (75 mm Hg vs. 50 mm Hg), P=0.01. ‡ 
Significant interaction between intervention and condition, P<0.001. 
Experimental Condition  PETO2 75 mmHg  PETO2  50 mmHg   
     
Experimental Intervention     Normoxia     Hypoxia     Normoxia Hypoxia  
FMD      
Baseline diameter (mm) 3.86 ± 0.73 3.85 ± 0.73 3.94 ± 0.70 4.12 ± 0.77 †‡ 
Baseline peak  blood flow velocity (cm·s-1)  8.4 ± 4.4 5.5 ± 2.8 8.6 ± 4.9 4.4 ± 2.6 * 
Baseline peak blood flow (ml·min) 66.2 ± 52.9    43.5 ± 32.5 70.7 ± 57.1 40.5 ± 34.4 * 
Peak diameter (mm) 4.12 ± 0.73 4.07 ± 0.75 4.21 ± 0.71 4.25 ± 0.78  
Time to peak diameter (s) 62 ± 27 46 ± 13 57 ± 27 56 ± 31  
SRAUC (AUC) 26546 ± 10249 20199 ± 9886 25163 ± 11096 18683 ± 11947 * 
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Table 3: Effect of normoxia and acute isocapnic hypoxia on GTN related variables  
 
 
 
 
 
 
 
 
 
 
Values expressed as mean ± SD: Shear rate area under the curve (SRAUC); Flow mediated 
dilation (FMD); Endothelium-independent FMD (GTN). * Significant main effect for 
intervention (normoxia vs hypoxia), P<0.0 
 
 
 
 
Table 4: FMD related variables prior to and following 30-minutes of supine normoxic rest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values expressed as mean ± SD: Shear rate area under the curve (SRAUC); Flow mediated 
dilation (FMD); Shear rate (SR). * †(Wilcoxon test)  Post 30-min significantly different from 
baseline; P<0.03. 
 
Experimental Condition  Normoxia PETO2 75 mmHg PETO2  50 mmHg  
GTN     
Baseline diameter (mm) 3.95 ± 0.69 3.99 ± 0.77 4.13 ± 0.72 * 
Peak diameter (mm)    4.61 ± 0.73 4.54 ± 0.77 4.63 ± 0.72  
Time to peak diameter (s) 450 ± 95 472 ± 82 453 ± 62  
FMD:GTN ratio  0.45 ± 0.20 0.40 ± 0.18 0.29 ± 0.17 * 
       Baseline  Post 30-min  
Baseline diameter (mm) 4.46 ± 0.42 4.39 ± 0.39  
Baseline blood flow velocity (cm·s-1)  16.0 ± 7.1 10.2 ± 5.9 * 
Baseline peak blood flow (ml·min) 162 ± 106 96 ± 70 * 
Baseline Mean SR (s) 111 ± 49 74 ± 42 † 
Baseline Anterograde SR (s) 120 ± 46 87 ± 38  
Baseline Retrograde SR (s) -8 ± 8 -13 ± 13  
Baseline Oscillatory SR Index  0.08 ± 0.09 0.13 ± 0.12  
Peak diameter (cm) 4.79 ± 0.35 4.69 ± 0.33 * 
Time to peak diameter (s) 61 ± 22 64 ± 30  
SRAUC (AUC) 30948 ± 10303 277 68± 11846  
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